Cargando…

Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis

BACKGROUND: As a first-line treatment regimen for Helicobacter pylori (H. pylori) infection, antibiotic therapy is widely used worldwide. However, the question of increasing antibiotic resistance must be considered. Given this issue, we need to find ways to reduce drug resistance. This study examine...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Shu-Peng, Cheng, Qian, Feng, Cheng-Yang, Xu, Chan, Sun, Ming-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782940/
https://www.ncbi.nlm.nih.gov/pubmed/36569016
http://dx.doi.org/10.12998/wjcc.v10.i35.12959
_version_ 1784857458948177920
author Zou, Shu-Peng
Cheng, Qian
Feng, Cheng-Yang
Xu, Chan
Sun, Ming-Hui
author_facet Zou, Shu-Peng
Cheng, Qian
Feng, Cheng-Yang
Xu, Chan
Sun, Ming-Hui
author_sort Zou, Shu-Peng
collection PubMed
description BACKGROUND: As a first-line treatment regimen for Helicobacter pylori (H. pylori) infection, antibiotic therapy is widely used worldwide. However, the question of increasing antibiotic resistance must be considered. Given this issue, we need to find ways to reduce drug resistance. This study examined all currently available first-line regimens and compared them with standard triple treatment through a network meta-analysis of randomized controlled trials (RCTs). AIM: To compare first-line treatment regimens for eradication of antibiotic-resistant H. pylori strains. METHODS: To compare the effectiveness of the first-line regimens for treating H. pylori infection, a Bayesian network meta-analysis was applied to process data extracted from RCTs. The plausible ranking for each regimen was assessed by the surface under the cumulative ranking curve (SUCRA). In addition, we conducted a relevant search by reference citation analysis. RESULTS: Twenty-five RCTs involving 12029 participants [including 1602 infected with clarithromycin (CAM)-resistant strains and 1716 infected with metronidazole (MNZ)-resistant strains] were included, in which a total of seven regimens were used for H. pylori eradication. The results showed that dual therapy containing a high-dose proton pump inhibitor (HDDT) [odds ratio (OR): 4.20, 95% confidence interval (CI): 2.29-8.13] was superior to other therapies for all patients, including those with CAM/MNZ-resistant H. pylori infection. In the comparative effectiveness ranking, for CAM-resistant H. pylori, HDDT (OR: 96.80, 95%CI: 22.46-521.9) had the best results, whereas standard triple therapy ranked last (SUCRA: 98.7% vs 0.3%). In the subgroup of high cure rates (≥ 90%), HDDT was also generally better than other therapies. CONCLUSION: For the eradication of CAM- and MNZ-resistant H. pylori strains, HDDT exhibited considerable advantages. The studies of CAM-resistant H. pylori were based on small samples due to a lack of antibiotic sensitivity tests in many RCTs, but the results showed that all patients, including those with CAM-resistant H. pylori infection, had a concordant trend. Overall, HDDT may be a reference for RCTs and other studies of H. pylori eradication.
format Online
Article
Text
id pubmed-9782940
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-97829402022-12-24 Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis Zou, Shu-Peng Cheng, Qian Feng, Cheng-Yang Xu, Chan Sun, Ming-Hui World J Clin Cases Meta-Analysis BACKGROUND: As a first-line treatment regimen for Helicobacter pylori (H. pylori) infection, antibiotic therapy is widely used worldwide. However, the question of increasing antibiotic resistance must be considered. Given this issue, we need to find ways to reduce drug resistance. This study examined all currently available first-line regimens and compared them with standard triple treatment through a network meta-analysis of randomized controlled trials (RCTs). AIM: To compare first-line treatment regimens for eradication of antibiotic-resistant H. pylori strains. METHODS: To compare the effectiveness of the first-line regimens for treating H. pylori infection, a Bayesian network meta-analysis was applied to process data extracted from RCTs. The plausible ranking for each regimen was assessed by the surface under the cumulative ranking curve (SUCRA). In addition, we conducted a relevant search by reference citation analysis. RESULTS: Twenty-five RCTs involving 12029 participants [including 1602 infected with clarithromycin (CAM)-resistant strains and 1716 infected with metronidazole (MNZ)-resistant strains] were included, in which a total of seven regimens were used for H. pylori eradication. The results showed that dual therapy containing a high-dose proton pump inhibitor (HDDT) [odds ratio (OR): 4.20, 95% confidence interval (CI): 2.29-8.13] was superior to other therapies for all patients, including those with CAM/MNZ-resistant H. pylori infection. In the comparative effectiveness ranking, for CAM-resistant H. pylori, HDDT (OR: 96.80, 95%CI: 22.46-521.9) had the best results, whereas standard triple therapy ranked last (SUCRA: 98.7% vs 0.3%). In the subgroup of high cure rates (≥ 90%), HDDT was also generally better than other therapies. CONCLUSION: For the eradication of CAM- and MNZ-resistant H. pylori strains, HDDT exhibited considerable advantages. The studies of CAM-resistant H. pylori were based on small samples due to a lack of antibiotic sensitivity tests in many RCTs, but the results showed that all patients, including those with CAM-resistant H. pylori infection, had a concordant trend. Overall, HDDT may be a reference for RCTs and other studies of H. pylori eradication. Baishideng Publishing Group Inc 2022-12-16 2022-12-16 /pmc/articles/PMC9782940/ /pubmed/36569016 http://dx.doi.org/10.12998/wjcc.v10.i35.12959 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Meta-Analysis
Zou, Shu-Peng
Cheng, Qian
Feng, Cheng-Yang
Xu, Chan
Sun, Ming-Hui
Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
title Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
title_full Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
title_fullStr Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
title_full_unstemmed Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
title_short Comparative effectiveness of first-line therapies for eradication of antibiotic-resistant Helicobacter pylori strains: A network meta-analysis
title_sort comparative effectiveness of first-line therapies for eradication of antibiotic-resistant helicobacter pylori strains: a network meta-analysis
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782940/
https://www.ncbi.nlm.nih.gov/pubmed/36569016
http://dx.doi.org/10.12998/wjcc.v10.i35.12959
work_keys_str_mv AT zoushupeng comparativeeffectivenessoffirstlinetherapiesforeradicationofantibioticresistanthelicobacterpyloristrainsanetworkmetaanalysis
AT chengqian comparativeeffectivenessoffirstlinetherapiesforeradicationofantibioticresistanthelicobacterpyloristrainsanetworkmetaanalysis
AT fengchengyang comparativeeffectivenessoffirstlinetherapiesforeradicationofantibioticresistanthelicobacterpyloristrainsanetworkmetaanalysis
AT xuchan comparativeeffectivenessoffirstlinetherapiesforeradicationofantibioticresistanthelicobacterpyloristrainsanetworkmetaanalysis
AT sunminghui comparativeeffectivenessoffirstlinetherapiesforeradicationofantibioticresistanthelicobacterpyloristrainsanetworkmetaanalysis